Literature DB >> 3145796

Short- and long-term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomized rats.

A Stutzer1, H Fleisch, U Trechsel.   

Abstract

The inhibitory effect of a single subcutaneous (s.c.) dose of three different bisphosphonates (Bps)--4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP), 2-(2-pyridinyl)-ethylidene-1,1-bisphosphonate (2-PEBP), and dichloromethylene-bisphosphonate (Cl2MBP)--was studied in a model of retinoid-induced bone resorption, which consists of assessing the hypercalcemic effect of the arotinoid Ro 13-6298 given s.c. for three days in thyroparathyroidectomized (TPTX) rats. The retinoid was given on day 0, 1, and 2. Bps were administered together with or at different times prior to the first dose of retinoid. A dose-dependent inhibition was obtained with all three compounds. AHBuBP produced complete inhibition which remained for 3 weeks at 0.1 mg P/kg. The dose-response curves were identical when the compound was given on the first day of retinoid administration (day 0) or 6 days earlier. With 2-PEBP, the dose-response curve was the same as that for AHBuBP when given on day 0. When given 6 days earlier, the curve was shifted to 30 times less potency. Cl2MBP was about 100 times less potent than AHBuBP when given on day 0, with 3 mg P/kg producing complete inhibition. When given 6 days earlier, the curve was also shifted to 10 times less potency, and even 30 mg P/kg failed to produce complete inhibition. With 10 mg P/kg, the inhibitory effect was maintained partially for up to 3 weeks. This study shows that in this model of bone resorption the inhibitory effect of a single dose of certain Bps is effective for at least 3 weeks and that the compounds vary in their activity over time.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145796     DOI: 10.1007/bf02556639

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  14 in total

1.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

2.  Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

Authors:  R D Altman; C C Johnston; M R Khairi; H Wellman; A N Serafini; R R Sankey
Journal:  N Engl J Med       Date:  1973-12-27       Impact factor: 91.245

3.  Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.

Authors:  A Jung
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

4.  Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo.

Authors:  U Trechsel; A Stutzer; H Fleisch
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

5.  Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats.

Authors:  R Schenk; W A Merz; R Mühlbauer; R G Russell; H Fleisch
Journal:  Calcif Tissue Res       Date:  1973-03-12

6.  A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.

Authors:  D Thiébaud; P Jaeger; A F Jacquet; P Burckhardt
Journal:  J Bone Miner Res       Date:  1986-12       Impact factor: 6.741

7.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

8.  Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse.

Authors:  P J Marie; M Hott; M T Garba
Journal:  Bone       Date:  1985       Impact factor: 4.398

9.  Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages.

Authors:  M G Cecchini; R Felix; H Fleisch; P H Cooper
Journal:  J Bone Miner Res       Date:  1987-04       Impact factor: 6.741

10.  Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.

Authors:  D L Douglas; T Duckworth; R G Russell; J A Kanis; C J Preston; F E Preston; M A Prenton; J S Woodhead
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

View more
  5 in total

1.  Hyperostosis induced by the bisphosphonate (2-PEBP) in the oophorectomized rat.

Authors:  C Movsowitz; S Epstein; M Fallon; F Ismail; S Thomas
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet.

Authors:  V N Antic; H Fleisch; R C Mühlbauer
Journal:  Calcif Tissue Int       Date:  1996-06       Impact factor: 4.333

4.  Inhibition of bone mineral loss during lactation by Cl2MBP.

Authors:  R Brommage; D C Baxter
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

5.  Uncoupling of invasive bacterial mucosal immunogenicity from pathogenicity.

Authors:  Simona P Pfister; Olivier P Schären; Luca Beldi; Andrea Printz; Matheus D Notter; Mohana Mukherjee; Hai Li; Julien P Limenitakis; Joel P Werren; Disha Tandon; Miguelangel Cuenca; Stefanie Hagemann; Stephanie S Uster; Miguel A Terrazos; Mercedes Gomez de Agüero; Christian M Schürch; Fernanda M Coelho; Roy Curtiss; Emma Slack; Maria L Balmer; Siegfried Hapfelmeier
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.